CRN’s Steve Mister welcomes new members
WASHINGTON — Council for Responsible Nutrition president and CEO Steve Mister on Wednesday published a new video welcoming new members to the association.
“We want you to get the most out of our membership,” Mister said in the video. “You’ll get the best benefit from your membership from being involed.” Mister suggested new members dive in by paticipating in work groups, committees and task forces on everything from communications and media outreach to government relations and regulatory affairs.
“Don’t forget about our many in-person events for education and networking throughout the year,” Mister added. In October, CRN will hold its industry annual symposium at the Ritz-Carlton, Dove Mountain, in Marana, Ariz. The day prior to the annual meeting, CRN will host a keynote address from Rachel Johnson, professor of nutrition and pediatrics, University of Vermont, who will speak to improving the nutrient status of American women and children by way of balance and choice in the Women, Infants, and Children (WIC) supplemental nutrition program.
CRN in July welcomed 11 new companies to the association’s membership roster, including Natrol.
Entia Biosciences launches supplement supporting kidney health
PORTLAND, Ore. — Entia Biosciences on Monday announced the launch of Ergo4Health/Kidney, a new nutritional supplement intended for individuals who are concerned about kidney health. The product comes in easy-to-swallow 500 mg capsules.
Ergo4Health/Kidney provides an essential amino acid L-ergothioneine ("Ergo"). Ergo is an antioxidant found only in food and is not created by the body. Research has further shown that Ergo is found in abundance in cells exposed to the highest amounts of oxidative stress such as the kidney, brain, liver, etc., where it is postulated to be needed most, noted Marvin Hausman, chief science and technology officer for Entia Biosciences.
Hausman had a scientific poster accepted for presentation at the National Kidney Foundation Meeting held during April 2017 in Orlando. The presentation highlighted the effect of Ergo4Health/Kidney on important kidney function bio-markers such as: eGFR (estimated Glomerular Filtration Rate), Creatinine and BUN (blood urea nitrogen).
Acura completes Nexafed transition to MainPointe with new formulation on horizon
PALATINE, Ill. — Acura Pharmaceuticals on Monday reported the completed transition of Nexafed and Nexafed Sinus to MainPointe Pharmaceuticals as that company commences selling activities with a new formulation coming to market soon.
"Consistent with our strategy to secure licensing partners to commercialize our product technologies, in March the company licensed Nexafed and Nexafed Sinus to MainPointe Pharmaceuticals and recorded license fee revenue of $2.5 million," Peter Clemens, SVP and CFO Acura, told analysts earlier this week. "We expect the sales to grow significantly over current levels as MainPointe brings their commercial expertise to bear to penetrate the pharmacy market."
MainPointe will be bringing to market Nexafed 2.0, added Bob Jones, Acura president and CEO. "We have completed manufacturing validation for Nexafed with our [microparticle] 2.0 formulation," he said. "The output from these batches has been transferred to MainPointe and is available for sale. We expect MainPointe will introduce Nexafed 2.0 to the market in this the third quarter."
"Conversion of pseudoephedrine products into methamphetamine remains an acute problem in many communities," John Schutte, MainPointe chairman and CEO, noted earlier this year in acquiring the rights to market Nexafed. "The Nexafed products have proven to be a success in curbing this costly problem and we look forward to driving this business forward."